LivingGLP1
Descriptive only

Vomiting

Polycystic ovary syndrome

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)Separate part 2 of a disconnected network
2
Randomized trials
3
Treatments
118
Participants
12
Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
DULA_SC_1p5MG_QWEXENER_SC_2MG_QWSTANDARD_CARE
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialSex (percent female)
effect modifier, prognostic factor; 1 of 2
NCT04876027
S000699
not reported
NCT04029272
S000952
100

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • FlagBaseline, Sex: not reported by 1 of 2 trials
  • NoteOutcome assessment, time point: selected time points span 12 to 26.07 weeks
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
NCT0487602726.07randomizednot statednot statednot statednot statednot statednot statedopen_labelnon_industry2021women 18 to 45, BMI 24 or higher, PCOS by Rotterdam criteria
NCT0402927212randomizednot statednot statednot statednot statednot statednot statedopen_labelnon_industry2019women 18 to 40 years; Rotterdam PCOS; BMI 25 or more; no diabetes

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
NCT04876027A1DULA_SC_1p5MG_QW26.07arm, events7 / 35R0009547:Table 3
NCT04876027A2STANDARD_CARE26.07arm, events0 / 33R0009547:Table 3
NCT04029272A1STANDARD_CARE12arm, events3 / 25R0011463:Table 4
NCT04029272A2EXENER_SC_2MG_QW12arm, events2 / 25R0011463:Table 4

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab